Welcome!

News Feed Item

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703947/Aortic-Valve-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Aortic Valve Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Aortic Valve Stenosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Aortic Valve Stenosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Aortic Valve Stenosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Unaccomplished Trials of Aortic Valve Stenosis 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Aortic Valve Stenosis Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
Edwards Lifesciences Corporation 30
Clinical Trial Overview of Edwards Lifesciences Corporation 30
CryoLife, Inc. 31
Clinical Trial Overview of CryoLife, Inc. 31
AstraZeneca PLC 32
Clinical Trial Overview of AstraZeneca PLC 32
Pfizer Inc. 33
Clinical Trial Overview of Pfizer Inc. 33
Merck & Co., Inc. 34
Clinical Trial Overview of Merck & Co., Inc. 34
Direct Flow Medical, Inc. 35
Clinical Trial Overview of Direct Flow Medical, Inc. 35
Cerenis Therapeutics SA 36
Clinical Trial Overview of Cerenis Therapeutics SA 36
A. Menarini Industrie Farmaceutiche Riunite Srl 37
Clinical Trial Overview of A. Menarini Industrie Farmaceutiche Riunite Srl 37
Clinical Trial Overview of Top Institutes / Government 38
National Heart, Lung, and Blood Institute 38
Clinical Trial Overview of National Heart, Lung, and Blood Institute 38
Erasmus MC 39
Clinical Trial Overview of Erasmus MC 39
Assistance Publique - Hopitaux de Paris 40
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 40
Washington University School of Medicine 41
Clinical Trial Overview of Washington University School of Medicine 41
Charles University 42
Clinical Trial Overview of Charles University 42
University of Edinburgh 43
Clinical Trial Overview of University of Edinburgh 43
Asan Medical Center 44
Clinical Trial Overview of Asan Medical Center 44
Helsinki University Central Hospital 45
Clinical Trial Overview of Helsinki University Central Hospital 45
Aarhus University Hospital 46
Clinical Trial Overview of Aarhus University Hospital 46
Sahlgrenska University Hospital 47
Clinical Trial Overview of Sahlgrenska University Hospital 47
Five Key Clinical Profiles 48
Appendix 69
Abbreviations 69
Definitions 69
Research Methodology 70
Secondary Research 70
About GlobalData 71
Contact Us 71
Disclaimer 71
Source 71

List of Tables
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Aortic Valve Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Aortic Valve Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Aortic Valve Stenosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Aortic Valve Stenosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Aortic Valve Stenosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Phase, 2014* 19
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 20
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Aortic Valve Stenosis Therapeutics, Global, Suspended Clinical Trials, 2014* 23
Aortic Valve Stenosis Therapeutics, Global, Terminated Clinical Trials, 2014* 23
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 24
Aortic Valve Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 25
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 26
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Edwards Lifesciences Corporation, 2014* 30
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by CryoLife, Inc., 2014* 31
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 32
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 33
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 34
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Direct Flow Medical, Inc., 2014* 35
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cerenis Therapeutics SA, 2014* 36
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by A. Menarini Industrie Farmaceutiche Riunite Srl, 2014* 37
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 38
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2014* 39
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 40
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 41
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Charles University, 2014* 42
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Edinburgh, 2014* 43
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Asan Medical Center, 2014* 44
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Helsinki University Central Hospital, 2014* 45
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Aarhus University Hospital, 2014* 46
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sahlgrenska University Hospital, 2014* 47

List of Figures
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Aortic Valve Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Aortic Valve Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Aortic Valve Stenosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 19
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 20
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 24
Aortic Valve Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 25
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 26
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 27
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
GlobalData Methodology 70


Read the full report:
Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703947/Aortic-Valve-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: imple...
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, will discuss how by using...
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
SYS-CON Events announced today that CAST Software will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CAST was founded more than 25 years ago to make the invisible visible. Built around the idea that even the best analytics on the market still leave blind spots for technical teams looking to deliver better software and prevent outages, CAST provides the software intelligence that matter ...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
SYS-CON Events announced today that Daiya Industry will exhibit at the Japanese Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Ruby Development Inc. builds new services in short period of time and provides a continuous support of those services based on Ruby on Rails. For more information, please visit https://github.com/RubyDevInc.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
As businesses evolve, they need technology that is simple to help them succeed today and flexible enough to help them build for tomorrow. Chrome is fit for the workplace of the future — providing a secure, consistent user experience across a range of devices that can be used anywhere. In her session at 21st Cloud Expo, Vidya Nagarajan, a Senior Product Manager at Google, will take a look at various options as to how ChromeOS can be leveraged to interact with people on the devices, and formats th...
First generation hyperconverged solutions have taken the data center by storm, rapidly proliferating in pockets everywhere to provide further consolidation of floor space and workloads. These first generation solutions are not without challenges, however. In his session at 21st Cloud Expo, Wes Talbert, a Principal Architect and results-driven enterprise sales leader at NetApp, will discuss how the HCI solution of tomorrow will integrate with the public cloud to deliver a quality hybrid cloud e...
SYS-CON Events announced today that Yuasa System will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Yuasa System is introducing a multi-purpose endurance testing system for flexible displays, OLED devices, flexible substrates, flat cables, and films in smartphones, wearables, automobiles, and healthcare.
Is advanced scheduling in Kubernetes achievable? Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, will answer these questions and demonstrate techniques for implementing advanced scheduling. For example, using spot instances ...
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Taica manufacturers Alpha-GEL brand silicone components and materials, which maintain outstanding performance over a wide temperature range -40C to +200C. For more information, visit http://www.taica.co.jp/english/.